{"id":74945,"date":"2023-10-23T11:47:17","date_gmt":"2023-10-23T15:47:17","guid":{"rendered":"https:\/\/hitconsultant.net\/?p=74945"},"modified":"2023-10-26T16:51:20","modified_gmt":"2023-10-26T20:51:20","slug":"pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment","status":"publish","type":"post","link":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/","title":{"rendered":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" width=\"400\" height=\"400\" src=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770.jpeg\" alt=\"\" class=\"wp-image-74946\" srcset=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770.jpeg 400w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770-300x300.jpeg 300w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770-290x290.jpeg 290w, https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770-100x100.jpeg 100w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/><\/figure>\n\n\n\n<p><strong>What You Should Know:<\/strong><\/p>\n\n\n\n<ul><li><a href=\"https:\/\/pangeabiomed.com\/\">Pangea Biomed<\/a>, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients.<\/li><li>Fibrolamellar carcinoma (FLC) is a rare liver cancer that typically presents in young adolescents and young adults at a median age of 22 who have no history of liver disease. There is no clear standard of care for the disease, and in the setting of metastatic disease, 5-year survival rates are approximately 39 percent<\/li><\/ul>\n\n\n\n<p><strong>Expanding Horizons in the Treatment for Fibrolamellar Carcinoma<\/strong><\/p>\n\n\n\n<p>\u201cSince FLC makes up about 1% of all primary liver cancers, there is limited data on the disease, which impedes treatment,\u201d said Pangea CEO Tuvik Beker, Ph.D. \u201cFortunately, by design, ENLIGHT is able to surface relevant insights specific to a patient\u2019s tumor even without significant training datasets.\u201d<\/p>\n\n\n\n<p>Using ENLIGHT, which leverages unsupervised learning and sequenced tumor transcriptomics, Pangea will suggest treatments for FLC patients that FibroFighters work with, compare treatment response predictions against treatment outcomes, as well as with ex-vivo models, and refine models for treatment response and resistance.&nbsp;n December 2022, Pangea published a case study in the Journal for ImmunoTherapy of Cancer on the ENLIGHT-matched treatment of an FLC patient. Despite common biomarkers for immune checkpoint blockade (ICB) coming back negative, the patient went into complete remission after being treated with an ENLIGHT-matched combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>What You Should Know: Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its partnership with patient-centric advocacy organization FibroFighters to advance treatment for fibrolamellar carcinoma (FLC) patients. Fibrolamellar carcinoma (FLC) is a rare liver cancer that typically presents in young adolescents and young adults at a median age of 22 <a class=\"more-posts-link\" href=\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\">&#8230; Read More<\/a><\/p>\n","protected":false},"author":94,"featured_media":74946,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[25444],"tags":[2581],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.6 (Yoast SEO v20.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment -<\/title>\n<meta name=\"description\" content=\"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-23T15:47:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-26T20:51:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Syed Hamza Sohail\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:site\" content=\"@hitconsultant\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Syed Hamza Sohail\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\"},\"author\":{\"name\":\"Syed Hamza Sohail\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f\"},\"headline\":\"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment\",\"datePublished\":\"2023-10-23T15:47:17+00:00\",\"dateModified\":\"2023-10-26T20:51:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\"},\"wordCount\":244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"keywords\":[\"Oncology\"],\"articleSection\":[\"Life Sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\",\"url\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\",\"name\":\"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment -\",\"isPartOf\":{\"@id\":\"https:\/\/hitconsultant.net\/#website\"},\"datePublished\":\"2023-10-23T15:47:17+00:00\",\"dateModified\":\"2023-10-26T20:51:20+00:00\",\"description\":\"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its\",\"breadcrumb\":{\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hitconsultant.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Life Sciences\",\"item\":\"https:\/\/hitconsultant.net\/category\/life-sciences\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hitconsultant.net\/#website\",\"url\":\"https:\/\/hitconsultant.net\/\",\"name\":\"\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/hitconsultant.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hitconsultant.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/hitconsultant.net\/#organization\",\"name\":\"HIT Consultant Media\",\"url\":\"https:\/\/hitconsultant.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"contentUrl\":\"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png\",\"width\":\"1024\",\"height\":\"772\",\"caption\":\"HIT Consultant Media\"},\"image\":{\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409\",\"https:\/\/twitter.com\/hitconsultant\",\"http:\/\/www.linkedin.com\/company\/2489253\",\"https:\/\/www.pinterest.com\/hitconsultant\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f\",\"name\":\"Syed Hamza Sohail\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g\",\"caption\":\"Syed Hamza Sohail\"},\"url\":\"https:\/\/hitconsultant.net\/author\/ssohail\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment -","description":"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment","og_description":"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its","og_url":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/","article_publisher":"https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","article_published_time":"2023-10-23T15:47:17+00:00","article_modified_time":"2023-10-26T20:51:20+00:00","og_image":[{"width":400,"height":400,"url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2023\/10\/IMG_2770.jpeg","type":"image\/jpeg"}],"author":"Syed Hamza Sohail","twitter_card":"summary_large_image","twitter_creator":"@hitconsultant","twitter_site":"@hitconsultant","twitter_misc":{"Written by":"Syed Hamza Sohail","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/"},"author":{"name":"Syed Hamza Sohail","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f"},"headline":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment","datePublished":"2023-10-23T15:47:17+00:00","dateModified":"2023-10-26T20:51:20+00:00","mainEntityOfPage":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/"},"wordCount":244,"commentCount":0,"publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"keywords":["Oncology"],"articleSection":["Life Sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/","url":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/","name":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment -","isPartOf":{"@id":"https:\/\/hitconsultant.net\/#website"},"datePublished":"2023-10-23T15:47:17+00:00","dateModified":"2023-10-26T20:51:20+00:00","description":"Pangea Biomed, the startup behind the innovative treatment response predictor, ENLIGHT, today announced its","breadcrumb":{"@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hitconsultant.net\/2023\/10\/23\/pangea-fibrofighters-partner-to-advance-rare-liver-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hitconsultant.net\/"},{"@type":"ListItem","position":2,"name":"Life Sciences","item":"https:\/\/hitconsultant.net\/category\/life-sciences\/"},{"@type":"ListItem","position":3,"name":"Pangea, FibroFighters Partner to Advance Rare Liver Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/hitconsultant.net\/#website","url":"https:\/\/hitconsultant.net\/","name":"","description":"","publisher":{"@id":"https:\/\/hitconsultant.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hitconsultant.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/hitconsultant.net\/#organization","name":"HIT Consultant Media","url":"https:\/\/hitconsultant.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/","url":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","contentUrl":"https:\/\/hitconsultant.net\/wp-content\/uploads\/2012\/08\/hit_consultant_logo.png","width":"1024","height":"772","caption":"HIT Consultant Media"},"image":{"@id":"https:\/\/hitconsultant.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pages\/HIT-Consultant-Media\/302199219847409","https:\/\/twitter.com\/hitconsultant","http:\/\/www.linkedin.com\/company\/2489253","https:\/\/www.pinterest.com\/hitconsultant\/"]},{"@type":"Person","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/2c3b22c89b4967fe57f40b1f2fecab8f","name":"Syed Hamza Sohail","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hitconsultant.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3b32d24fb71fbe1a5b4e21c51b7ca22?s=96&d=mm&r=g","caption":"Syed Hamza Sohail"},"url":"https:\/\/hitconsultant.net\/author\/ssohail\/"}]}},"_links":{"self":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/74945"}],"collection":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/users\/94"}],"replies":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/comments?post=74945"}],"version-history":[{"count":0,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/posts\/74945\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media\/74946"}],"wp:attachment":[{"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/media?parent=74945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/categories?post=74945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hitconsultant.net\/wp-json\/wp\/v2\/tags?post=74945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}